Why ARNT Prostate Tumors Responding to Enzalutamide?
- PMID: 36052502
- DOI: 10.1158/2159-8290.CD-22-0702
Why ARNT Prostate Tumors Responding to Enzalutamide?
Abstract
Prostate tumors can develop resistance to androgen receptor (AR)-targeted therapies through treatment-induced changes in transcription factor activity that promote transcriptional and morphologic features of a neuroendocrine lineage. This study identifies an unexpected role for the circadian protein ARNTL in resistance to enzalutamide, a second-generation AR-targeted therapy. See related article by Linder et al., p. 2074 (4).
Trial registration: ClinicalTrials.gov NCT03297385.
©2022 American Association for Cancer Research.
Comment on
-
Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.Cancer Discov. 2022 Sep 2;12(9):2074-2097. doi: 10.1158/2159-8290.CD-21-0576. Cancer Discov. 2022. PMID: 35754340 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
